Hypokalemic periodic paralysis (hypoKPP) is a genetically determined disease characterized by episodic decreases in serum potassium levels accompanied by muscle weakness or paralysis. A case is reported and a review of the literature presented.
Current evidence suggests that the primary defect associated with hypoKPP resides either in the muscle cell membranes or in the cellular metabolism and gives rise to a conduction defect which results in muscle paralysis. A variety of drugs have been employed to correct the cellular abnormality, including supplemental potassium, diuretics, propranolol and diazoxide. To date the most effective therapy is acetazolamide, which induces a mild metabolic acidosis thought to stabilize the cellular membrane against intracellular shifts of potassium ions.
Get full access to this article
View all access options for this article.
References
1.
McArdleB.: Metabolic and Endocrine Myopathies, InWaltonJ. N. (Ed.): Disorders of Voluntary Muscle, 3rd Ed., Churchill and Livingston Company, London, pp. 726–729, 1974.
2.
PearsonC. M.KalyanaramanK.: The Periodic Paralyses. InStanburyJ. B.WyngaardenJ. B.FredricksonD. S. (Eds.): The Metabolic Basis of Inherited Disease, 3rd Ed., McGraw-Hill, New York, N.Y., pp. 1181–1192, 1972.
StreetenD. H. P.: Periodic Paralysis. InStanburyJ. B.WyngaardenJ. B.FredricksonD. S. (Eds.): The Metabolic Basis of Inherited Disease, 2nd Ed., McGraw-Hill, New York, N.Y., pp. 905–938, 1966.
10.
MeyersK. R.: A Summary Review of the Diagnosis and Pathology of the Primary Familial Periodic Paralyses, Ann. Clin. Lab. Sci.5: 216–221 (Mar.) 1975.
11.
EngelA. G.PotterC. S.RosevearJ. W.: Studies on Carbohydrate Metabolism and Mitochondrial Respiratory Activities in Primary Hypokalemic Periodic Paralysis, Neurology17: 329–336 (Apr.) 1967.
12.
ShyG. M.WankoT.RowleyP. T.: Studies in Familial Periodic Paralysis, Exp. Neurol.3: 53–121 (Jan.) 1961.
13.
ConnJ. W.StreetenD. H. P.: Periodic Paralysis. InStanburyJ. B.WyngaardenJ. B.FredricksonD. S. (Eds.): The Metabolic Basis of Inherited Disease, 1st Ed., McGraw-Hill, New York, N.Y. pp. 867–918, 1960.
14.
RowleyP. T.KilmanB.: The Effect of Sodium Loading and Depletion on Muscular Strength and Aldosterone Excretion in Familial Periodic Paralysis, Am. J. Med.28: 376–385 (Mar.) 1960.
15.
AitkenR. S.AllottL. I. M.CastledenL. I. N.: Observations on a Case of Familial Periodic Paralysis, Clin. Sci.3: 47–57 (July) 1937.
16.
McQuarrieI.ZieglerM. R.: Hereditary Periodic Paralysis, Metabolism1: 116–143 (Mar.) 1952.
17.
PearsonC. M.: The Periodic Paralyses; Differential Features and Pathological Observations in Permanent Myopathic Weakness, Brain87: 341–354 (June) 1964.
18.
ResnickJ. S.EngelW. K.GriggsR. C.: Acetazolamide Prophylaxis in Hypokalemic Periodic Paralysis, N. Engl. J. Med.278: 582–586 (Mar. 14) 1968.
19.
PoskanzerD. C.KerrD. N. S.: Periodic Paralysis with Response to Spironolactone, Lancet2: 511–513 (Sept. 2) 1961.
20.
OkinakaS.OhsawaN.ShizumeK.: Effect of Aldosterone Antagonist on Periodic Paralysis, J. Clin. Endocrinol. Metabol.22: 549–551 (May) 1962.
21.
GriggsR. C.EngelW. K.ResnickJ. S.: Acetazolamide Treatment of Hypokalemic Periodic Paralysis, Ann. Intern. Med.73: 39–48 (July) 1970.
22.
VroomF. Q.JarrellM. A.MarenT. H.: Acetazolamide Treatment of Hypokalemic Periodic Paralysis: A Probable Mechanism of Action, Arch. Neurol.32: 385–392 (June) 1975.
23.
Anon.: Diamox® (Package Insert), Lederle Laboratories, Pearl River, New York, 1973.
24.
JohnsenT.: The Treatment of Familial Periodic Hypokalemia with Propranolol, Acta Neurol. Scand.56: 613–619 (Dec.) 1977.
25.
JohnsenT.: Effect upon Serum Insulin, Glucose and Potassium Concentrations of Acetazolamide Drug Attacks of Familial Periodic Hypokalemic Paralysis, Acta Neurol. Scand.56: 533–541 (Dec.) 1977.
26.
JohnsenT.: Trial of the Prophylactic Effect of Diazoxide in the Treatment of Familial Periodic Paralysis, Acta Neurol. Scand.56: 525–532 (Dec.) 1977.
